A Phase 1 interventional study of Repotrectinib and Metformin in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Repotrectinib · Drug: Metformin · Drug: Digoxin · Drug: Rosuvastatin
Drug: Repotrectinib · Drug: Bupropion · Drug: Flurbiprofen · Drug: Omeprazole
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin.
Time frame: Up to approximately Day 17 post dose
Cohort 1: AUC (0-T) of Probe Substrate Without Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin.
Time frame: Up to approximately Day 17 post dose
Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin.
Time frame: Up to approximately Day 17 post dose
Cohort 1: AUC(INF) of Probe Substrate Without Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin.
Time frame: Up to approximately Day 17 post dose
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin
Time frame: Up to approximately Day 17 post dose
Cohort 1: Cmax of Probe Substrate Without Repotrectinib
Probe substrate contains metformin, digoxin, and rosuvastatin
Time frame: Up to approximately Day 17 post dose
Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With Repotrectinib
Time frame: Up to approximately Day 17 post dose
Cohort 1: AUC (0-48) of Metformin Without Repotrectinib
Time frame: Up to approximately Day 17 post dose
Cohort 1: Renal Clearance (CLR) of Metformin in Urine
Time frame: Up to approximately Day 16 post dose
Cohort 2: AUC (0-T) of Probe Substrate With Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Cohort 2: AUC (0-T) of Probe Substrate Without Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Cohort 2: AUC (INF) of Probe Substrate With Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Cohort 2: AUC (INF) of Probe Substrate Without Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Cohort 2: Cmax of Probe Substrate With Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Cohort 2: Cmax of Probe Substrate Without Repotrectinib
Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
Time frame: Up to approximately Day 17 post dose
Number of Participants with Adverse Events (AEs)
Time frame: Up to approximately Day 45 post dose
Number of Participants with Serious Adverse Events (SAEs)
Time frame: Up to approximately Day 45 post dose
Number of Participants With Clinically Significant Physical Examination Findings
Time frame: Up to approximately Day 17 post dose
Number of Participants With Clinically Significant Vital Sign Measurements
Time frame: Up to approximately Day 17 post dose
Number of Participants With Clinically Significant 12-lead Electrocardiogram (12-lead ECG) Findings
Time frame: Up to approximately Day 17 post dose
Number of Participants With Clinically Significant Safety Laboratory Test Results
Time frame: Up to approximately Day 17 post dose
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Dec 2025 to primary completion in Feb 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Repotrectinib